Abstract
Background: p53 mutations exist in many types of cancer and they are especially known in breast cancers. High expression of this protein has been associated with an adverse prognosis. Furthermore, previous studies have shown that p53 positive (p53+) tumors show a lower axillary tumor burden (ATB) compared with those p53 negative (p53-) tumors, because of a higher tendency for hematological dissemination. Here, we hypothesize that taking p53 expression levels into account together with other routine anatomic, pathologic and molecular factors, could improve the prediction of ATB in breast cancer patients, ultimately helping to personalize surgical treatments.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call